Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?

Lamb Weston Hlds

Pinduoduo Inc - ADR

Lamb Weston (LW), Pinduoduo (PDD), and Catalyst Pharmaceuticals (CPRX) have been selected as the top picks with a high net income ratio.

3 Top-Rated Profitable Stocks to Buy Using Net Income Ratio

Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy

Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII

Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Strength Seen in Catalyst (CPRX): Can Its 9.2% Jump Turn into More Strength?

Catalyst Pharmaceuticals (CPRX) receives a notice letter stating that Teva Pharmaceuticals has filed an application to the FDA seeking approval for a generic version of Firdapse.

Catalyst (CPRX) Down on TEVA's FDA Filing for Firdapse Generic

Announced Earlier Today-Notice Received from ANDA Filer for FIRDAPSE®

Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra

CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it has received a Paragraph IV Certification Notice Letter (the "Notice Letter") from Teva Pharmaceuticals, Inc. ("Teva") advising that Teva had submitted an Abbreviated New Drug Application ("ANDA") to the U.S. Food and Drug Administration ("FDA") seeking authorization from the FDA to manufacture, use or sell a generic version of FIRDAPSE® in the United States.

Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®

iShares Nasdaq Biotechnology ETF

Prometheus Biosciences

SAGE Therapeutics

SPDR S&P Biotech ETF

In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.

Biotech's Blockbuster Week: 3 Stocks to Watch

Harmony Biosciences Holdings

Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.

2 Biotechs Making Waves With A Single Product in their Pipeline

Catalyst (CPRX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Is Most-Watched Stock Catalyst Pharmaceuticals, Inc. (CPRX) Worth Betting on Now?

KLA-Tencor

Super Micro Computer

New Year starts with just three top stocks that meet IBD Sector Leaders' stringent criteria: Super Micro Computer, KLA and Catalyst Pharma. The post Sector Leaders End Tough Year With Thin Ranks appeared first on Investor's Business Daily.

Sector Leaders End Tough Year With Thin Ranks

Gilead Sciences

Moderna

The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval.

Biotech: 3 Profitable Bios Worth Owning

Genmab - ADR

Inspire Medical Systems Inc

Medpace Holdings

These leading biotech stocks have had a good quarter and some may have room to run, while for others it's time to ring the register. The post Biotech And Medical Stocks Leading Performers As 2022 Draws To A Close appeared first on Investor's Business Daily.

Biotech And Medical Stocks Leading Performers As 2022 Draws To A Close

Acquisition Expands The Company's Commercial Portfolio With An Established U.S. Marketed Product

Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd

It's practically printing cash, and even more is on the way.

This Growth Stock's Jaw-Dropping Run-Up Is Smashing Tesla's

Top stocks KLA, Super Micro Computer and Catalyst Pharmaceuticals are among sector leaders that are holding their ground. The post Top Stocks: Computer Hardware, Chip Equipment And Biotech Sector Leaders appeared first on Investor's Business Daily.

Top Stocks: Computer Hardware, Chip Equipment And Biotech Sector Leaders

UnitedHealth Group

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

Catalyst Pharmaceutical (CPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Catalyst (CPRX) Up 8.9% Since Last Earnings Report: Can It Continue?

Neurocrine Biosciences

Top biotech stocks surge within the IBD 50. Some pass buy points while others build bases.

Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build Bases

Catalyst Pharmaceuticals is in the process of entering new markets for its drug, Firdapse. It's also generating plenty of cash to spend on generating more growth.

Catalyst Pharmaceuticals: Undervalued And Likely To Outperform

Here is how Catalyst Pharmaceutical (CPRX) and DICE Therapeutics, Inc. (DICE) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?

Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.

Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Ali Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Jeffrey Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Conference Call Participants Les Sulewski - Truist Scott Henry - ROTH Capital Operator Good day, ladies and gentlemen and welcome to the Catalyst Pharmaceuticals Incorporated Third Quarter 2022 Financial Results Conference Call. All lines have been placed on a listen-only mode, and the floor will be open for questions and comments following the presentation.

Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2022 Earnings Call Transcript

Catalyst (CPRX) delivered earnings and revenue surprises of 5.26% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Catalyst Pharmaceuticals Stock (CPRX)